Design, synthesis, and preliminary pharmacological evaluation of 1, 4-diazabicyclo[4.3.0]nonan-9-ones as a new class of highly potent nootropic agents

J Med Chem. 2000 May 18;43(10):1969-74. doi: 10.1021/jm991170t.

Abstract

Several 4-substituted 1,4-diazabicyclo[4.3.0]nonan-9-ones have been synthesized and tested in vivo on mouse passive avoidance test, to evaluate their nootropic activity. The results show that they represent a new class of nootropic drugs with a pharmacological profile very similar to that of piracetam, showing much higher potency with respect to the reference. Among the compounds studied, 7 (DM 232) shows outstanding potency, being active at the dose of 0. 001 mg kg(-1) sc.

Publication types

  • Comparative Study
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adrenergic alpha-Agonists
  • Amnesia / chemically induced
  • Amnesia / drug therapy
  • Amnesia / prevention & control
  • Animals
  • Avoidance Learning / drug effects
  • Baclofen
  • Clonidine
  • Dose-Response Relationship, Drug
  • Drug Design*
  • GABA Agonists
  • Mecamylamine
  • Mice
  • Molecular Structure
  • Muscarinic Antagonists
  • Nicotine / antagonists & inhibitors
  • Nootropic Agents / chemical synthesis*
  • Nootropic Agents / pharmacology*
  • Piperazines / chemical synthesis*
  • Piperazines / pharmacology*
  • Piperazines / therapeutic use
  • Piracetam / pharmacology
  • Pyrroles / chemical synthesis*
  • Pyrroles / pharmacology*
  • Pyrroles / therapeutic use
  • Scopolamine

Substances

  • Adrenergic alpha-Agonists
  • GABA Agonists
  • Muscarinic Antagonists
  • Nootropic Agents
  • Piperazines
  • Pyrroles
  • Mecamylamine
  • Nicotine
  • Scopolamine
  • Baclofen
  • Clonidine
  • DM 232
  • Piracetam